“We have an ongoing subcutaneous Phase III clinical study in moderate to severe active TED. Fully enrolled, as we have shared and we expect to complete this study in the second half of this year.”

In context

“. Louise Chen: Hi, thanks for taking my question. I wanted to ask you about TEPEZZA and your thoughts on another potential competitor coming to market and then also where you stand with AMG seven thirty two for TED. Thank you. Robert A. Bradway: Okay, great. Maybe again we could do this in two chunks. Jay, you want to talk about the clinical piece and then Mirko talk about the commercial piece? James E. Bradner: Thanks, Louise. TEPEZZA is proving to be just a very important medicine. For the management of thyroid eye disease. We have established a very strong evidence base in both the high clinical activity score and lower clinical activity score patient populations that are quite proud of this data generation, and also the apparent impact that it's having on patients being treated today. We have an ongoing subcutaneous Phase III clinical study in moderate to severe active TED. Fully enrolled, as we have shared and we expect to complete this study in the second half of this year. So we have a really terrific medicine that's increasingly a standard of care that's helping a lot of patients and a strong data set that it sits on top of before handing off to Myrtle, I'll just quickly comment. On AMG seven thirty two. Thank you for noticing. This is an IGF-1R targeting monoclonal antibody. Also achieves subQT administration. Phase two studies enrolling, initially studied in moderate to severe and active TED. And we'll have more to say on that in the future. Murdo Gordon: Yep. Thanks, Jay. As Jay mentioned, we're expanding our treatment for patients with thyroid eye disease into the lower clinical activity score patient population who tends to be managed by different specialists than the higher clinical activity score patients. We have historically been able to drive ver”